Evaluating Meaningful Endpoints in Cancer Clinical Trials

This chapter explores a study from ASCO that critiques the use of surrogate endpoints like progression-free survival in cancer clinical trials. It highlights the disconnect between these metrics and patient priorities, while calling for regulatory changes to ensure improvements in overall survival and quality of life are prioritized.

Transcript

Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!

Get the app